SAGE Therapeutics Announces Six Scientific Presentations at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SAGE Therapeutics Announces Six Scientific Presentations at Neuroscience 2014, the Society for Neuroscience's 44th Annual Meeting

CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE ), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that six abstracts have been accepted for poster presentations at Neuroscience 2014, the Society for Neuroscience's 44 th Annual Meeting. The meeting will take place from November 15-19 at the Walter E. Washington Convention Center in Washington, DC.

Following is a schedule of SAGE's poster presentations:

Saturday, Nov. 15

Time: 4:00 PM - 5:00 PM
Location: WCC Hall A-C
Title: Pharmacological characterization of novel neuroactive steroid modulators of NMDA receptors

Sunday, Nov. 16

Time: 8:00 AM - 9:00 AM
Location: WCC Hall A-C
Title: A pharmacological characterization of novel neuroactive steroid modulators of GABA A receptors

Tuesday, Nov. 18

Time: 11:00 AM - 12:00 PM
Location: WCC Hall A-C
Title: Distributed kinetic effects of oxysterol positive modulators on NMDA channels

Wednesday, Nov. 19

Time: 8:00 AM - 9:00 AM
Location: WCC Hall A-C
Title: Allopregnanolone preclinical therapeutic development in relevant aging and Alzheimer ' s disease models

Time: 8:00 AM - 9:00 AM
Location: WCC Hall A-C
Title: A novel GABA A receptor positive allosteric modulator preferentially enhances extrasynaptic GABA A receptors and rescues deficient tonic GABAergic currents in a mouse model of Fragile-X Syndrome

Time: 10:00 AM - 11:00 AM
Location: WCC Hall A-C
Title: A new method for determining the degree of sedation in beagle dogs; validation with propofol and comparison to a novel compound

About SAGE Therapeutics

SAGE Therapeutics (Nasdaq: SAGE ) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus, or SRSE, and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit www.sagerx.com .

Forward-Looking Statements

This release contains forward-looking statements and information, including statements concerning SAGE's expectations regarding the potential safety, pharmacological effect and efficacy of SAGE-547, the expected development pathway for SAGE-547 and other product candidates and its expectations with respect to the timing and success of its clinical trials concerning its product candidates, and the applicability of the results from emergency-use cases to the population at large . These and other statements concerning SAGE's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In particular it should be noted that the initial data reported from the ongoing Phase 1/2 clinical trial of SAGE-547 are preliminary in nature and that the SAGE-547 clinical trial has not been completed. The preliminary data may change as additional data is released and such preliminary data may not be repeated or observed in ongoing or future studies involving SAGE-547 or SAGE's other product candidates. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE's ability to successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE's ability to manage operating expenses, SAGE's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as discussions of potential risks, uncertainties, and other important factors in SAGE's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE's views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements .

Media Contact: Dan Budwick, Pure Communications 973-271-6085 Investor Contact: Monique Allaire Lyons, Pure Communications 781-631-0759

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 92

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 22

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 14

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 21

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 286

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Canadian Solar's Storage Deal Has Real Staying Power

Updated Category News Views 18

Five battery projects and 22-year service contracts are the sort of details that make me stop squinting at renewable-energy headlines. Canadian Solar's e-STORAGE unit has signed agreements with X-ELIO to supply 590 MW and 1.43 GWh of battery energy storage across four Texas projects and one in New South Wales, Australia. That is not a vague memorandum, not a pilot, and...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 11

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 256

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 46

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading

Top 5 Most Recently Viewed Articles

Discovering Leo XIV: Insights Into Our First American Pope

Updated Category News Views 427

Introducing Leo XIV: The First American Pope Exciting news resonates across the Catholic community with the election of Leo XIV, the first American pope. EWTN Publishing is preparing to unveil the first comprehensive portrait of this monumental figure, appropriately titled LEO XIV: Portrait of the First American Pope. This intriguing book promises to offer valuable...

Continue Reading
nextSource Elevates Leadership with New COO to Enhance Growth

Updated Category News Views 144

nextSource Strengthens Leadership with Ronald LeVan as COO nextSource has made a significant move in its leadership by appointing Ronald LeVan as the new Chief Operating Officer. This change is part of the company’s strategic vision aimed at elevating client service standards and ensuring long-term growth. This appointment reflects a commitment to an innovative and...

Continue Reading
KBR Extends EPCM Partnership with Basra Oil Company Today

Updated Category News Views 193

KBR Renews Contract with Basra Oil Company KBR (NYSE: KBR) has exciting news to share—the company has successfully secured a two-year renewal of its engineering, procurement, and construction management (EPCM) contract with Basra Oil Company for operations at the Majnoon Oil Field. This extension strengthens KBR's position in the region and reflects the confidence BOC...

Continue Reading
Opendoor Stock Sees Surge Following CEO's Share Purchase

Updated Category News Views 174

Opendoor Technologies Inc. Stock Performance Opendoor Technologies Inc. (NASDAQ: OPEN) has witnessed a significant increase in its stock price as recent developments unfold. CEO Kaz Nejatian made a bold move by announcing his intent to purchase $1 million worth of company shares, which has positively influenced investor sentiment. CEO's Announcement Boosts Investor...

Continue Reading
Dr. Ellen Marmur Joins Forces with MedSpa Partners for Growth

Updated Category News Views 480

Dr. Ellen Marmur Joined MedSpa Partners to Enhance Aesthetic Care - MSP Begins the Year with the Addition of One of the Industry's Most Respected Practices - MedSpa Partners Inc. ("MSP") is excited to announce the recent partnership with Dr. Ellen Marmur and her esteemed team at Marmur Medical. With a dedicated focus on elevating the medical aesthetics landscape, this...

Continue Reading